[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.129.96. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
July 21, 2004

Suicide Risk and the SSRIs

Author Affiliations

Author Affiliations: Department of Psychological Medicine, Institute of Psychiatry, London, England.

JAMA. 2004;292(3):379-381. doi:10.1001/jama.292.3.379

The selective serotonin reuptake inhibitors (SSRIs) were a welcome innovation in the treatment of depression. Although these drugs are no more efficacious than their predecessors, they are safer in overdose and more acceptable in terms of adverse effects.1 The popularity of the SSRIs in general, and of fluoxetine (Prozac) in particular, created its own problems. For instance, Prozac achieved a recognition normally given to household items in which the brand name has become identified with the generic product.

First Page Preview View Large
First page PDF preview
First page PDF preview
×